Physician profile
Meredith Fox
NPI 1730437732
$2,077.65
in general payments reported to CMS, 2019-2025
20 companies · $661 in 2025
The $661 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $672 · 2023: $456 · 2024: $289 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,405.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.42 | 2022-2025 | |
| Novo Nordisk INC | $490.76 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $143.41 | 2022-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $114.76 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Y-Mabs Therapeutics, INC. | $102.92 | 2025 | Danyelza |
| Pfizer INC. | $86.09 | 2022-2024 | |
| Abbott Laboratories | $85.37 | 2022-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $78.92 | 2023-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $78.81 | 2025 | Korlym |
| Amgen INC. | $64.89 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.02 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.96 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $51.64 | 2022-2023 | Menveo, Bexsero, Shingrix |
| Axsome Therapeutics, INC. | $33.54 | 2024-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $29.71 | 2022-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $25.39 | 2025 | |
| Astellas Pharma US INC | $16.56 | 2024 | Veozah |
| Exact Sciences Corporation | $14.35 | 2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $13.60 | 2023 | |
| Phathom Pharmaceuticals, INC. | $4.53 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.